Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends RA drug

The UK's National Institute for Health and Clinical Excellence has issued final guidance recommending Centocor Ortho Biotech's rheumatoid arthritis drug Simponi in specific, limited circumstances

The UK's National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending Centocor Ortho Biotech's rheumatoid arthritis (RA) drug Simponi (golimumab) for use on the NHS in specific, limited circumstances.

The drug is recommended for adults with severe active RA used in combination with methotrexate in cases where 'conventional' disease-modifying antirheumatic drugs (DMARDs) have been ineffective.

It is also recommended for similar patients who have tried other types of DMARDs, including a tumour necrosis factor (TNF) inhibitor, but these treatments have also been ineffective and the patient is unable to take rituximab therapy for medical reasons or because of a previous bad reaction.

Dr Carole Longson, Health Technology Evaluation Centre director at NICE said: "This final guidance sets out the circumstances where golimumab can now be offered by the NHS as a treatment option for people with rheumatoid arthritis for whom previous treatments have not worked.

"Rheumatoid arthritis treatments help to relieve pain, improve mobility and reduce the long-term damage often experienced by people with this condition."

22nd June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics